MGA and cancer: In addition to the above and other reports in CLL, MGA inactivation, mostly involving terminating mutations or gene deletion (and nearly always hemizygous), have been described in as many as 10–20% of a variety of cancers including retinoblastomas, sporadic colorectal cancers, gastroenteropancreatic neuroendocrine tumors, gastrointestinal stromal cell tumors, lung squamous cell and adenocarcinomas, head and neck cancers and acute myelogenous leukemias (AML) [29,30,104,117,333,337,338,339,340,341,342,343,344,345,346].